Cyproheptadine Solution

Name: Cyproheptadine Solution

Cyproheptadine Solution Description

Each 5 mL (one teaspoonful) contains: Cyproheptadine Hydrochloride 2 mg

Inactive Ingredients: Alcohol 5%, citric acid, D&C Yellow #10, mint flavor, purified water, sodium citrate, sorbic acid (0.1% as preservative) and sucrose.

Cyproheptadine HCl is an antihistaminic and antiserotonergic agent. Cyproheptadine hydrochloride is a white to slightly yellowish, crystalline solid, with a molecular weight of 350.89, which is slightly soluble in water, freely soluble in methanol, sparingly soluble in ethanol, soluble in chloroform and practically insoluble in ether. It is the sesquihydrate of 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride. The molecular formula of the anhydrous salt is C21H21N•HCl and the structural formula of the anhydrous salt is:

Indications and Usage for Cyproheptadine Solution

Perennial and seasonal allergic rhinitis

Vasomotor rhinitis

Allergic conjunctivitis due to inhalant allergens and foods

Mild, uncomplicated allergic skin manifestations of urticaria and angioedema

Amelioration of allergic reactions to blood or plasma

Cold urticaria

Dermatographism

As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.

Contraindications

Newborn or Premature Infants: This drug should not be used in newborn or premature infants.

Nursing Mothers: Because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.

Other Conditions:

Hypersensitivity to cyproheptadine and other drugs of similar chemical structure

Monoamine oxidase inhibitor therapy (see Drug Interactions)

Angle-closure glaucoma

Stenosing peptic ulcer

Symptomatic prostatic hypertrophy

Bladder neck obstruction

Pyloroduodenal obstruction

Elderly, debilitated patients

Overdosage

Antihistamine overdosage reactions may vary from central nervous system depression to stimulation especially in children. Also, atropine-like signs and symptoms (dry mouth; fixed, dilated pupils; flushing, etc.) as well as gastrointestinal symptoms may occur.

If vomiting has not occurred spontaneously, the patient should be induced to vomit with syrup of ipecac.

If the patient is unable to vomit, perform gastric lavage followed by activated charcoal. Isotonic or 1/2 isotonic saline is the lavage of choice. Precautions against aspiration must be taken especially in infants and children. When life-threatening CNS signs and symptoms are present, intravenous physostigmine salicylate may be considered. Dosage and frequency of administration are dependent on age, clinical response and recurrence after response. (See package circulars for physostigmine products.)

Saline cathartics, as milk of magnesia, by osmosis draw water into the bowel and, therefore, are valuable for their action in rapid

dilution of bowel content.

Stimulants should not be used. Vasopressors may be used to treat hypotension.

The oral LD50 of cyproheptadine is 123 mg/kg, and 295 mg/kg in the mouse and rat, respectively.

PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label

Rx Only
NDC
39328-044-16

Cyproheptadine
Hydrochloride
Syrup

(Cyproheptadine Hydrochloride
Oral Solution, USP)

2 mg/5 mL

473 mL (16 FL. OZ.)

PATRIN
PHARMA

CYPROHEPTADINE HYDROCHLORIDE 
cyproheptadine hydrochloride solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:39328-044
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
CYPROHEPTADINE HYDROCHLORIDE (CYPROHEPTADINE) CYPROHEPTADINE HYDROCHLORIDE 2 mg  in 5 mL
Inactive Ingredients
Ingredient Name Strength
SORBIC ACID  
ALCOHOL  
ANHYDROUS CITRIC ACID  
TRISODIUM CITRATE DIHYDRATE  
SUCROSE  
MINT  
D&C YELLOW NO. 10  
WATER  
Product Characteristics
Color YELLOW Score     
Shape Size
Flavor MINT Imprint Code
Contains     
Packaging
# Item Code Package Description
1 NDC:39328-044-16 473 mL in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA204823 01/01/2017
Labeler - Patrin Pharma (806841677)
Registrant - Patrin Pharma (806841677)
Establishment
Name Address ID/FEI Operations
Bio-Pharm Inc. 801652546 MANUFACTURE(39328-044)
Revised: 02/2017   Patrin Pharma
(web3)